ClinicalTrials.gg
Not yet recruitingNCT07044999Updated Jul 1, 2025

Evaluation of Balance and Physical Performance Under Dual Task Conditions in Individuals With and Without Generalized Joint Hypermobility

An observational study in Hypermobility Syndrome, sponsored by Beylikduzu State Hospital. Not yet recruiting. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Beylikduzu State Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
2
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This study aims to evaluate balance and physical performance under dual task conditions in individuals with and without Generalized Joint Hypermobility (GJH), as determined by the Beighton score. All participants will undergo the One-Leg Stance Test and 30-Second Sit-to-Stand Test under both single-task (balance only) and dual-task (simultaneous cognitive task) conditions. The cognitive task will involve counting backward by sevens from a given number. Participants will also complete the Timed Up and Go (TUG) test under both single- and dual-task conditions. Additionally, the Berg Balance Scale (BBS) will be used for comprehensive balance assessment. Balance confidence will be evaluated using the Activities-specific Balance Confidence Scale (ABC-16), and fear of falling will be assessed with the Falls Efficacy Scale-International (FES-I). Changes in performance under dual-task conditions will be expressed as a percentage using the Dual Task Cost (DTC) formula

02

Conditions studied

  • Hypermobility Syndrome
03

In context

Lead sponsor

Beylikduzu State Hospital is the lead sponsor of 23 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

hypermobile patients and healthy controls

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 40 years
  • A Beighton score of 4 or higher (indicative of Generalized Joint Hypermobility)
  • Willingness to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 or older than 40 years
  • Presence of neurological disorders (e.g., stroke, multiple sclerosis, peripheral neuropathy)
  • History of vestibular system disorders (e.g., benign paroxysmal positional vertigo, vestibular neuritis)
  • History of orthopedic conditions affecting the lower extremities (e.g., fracture, joint replacement, ligament injury)
  • Cognitive impairment preventing the execution of cognitive tasks
  • Diagnosis of systemic musculoskeletal diseases (e.g., rheumatoid arthritis, Ehlers-Danlos syndrome)
  • Pregnancy
  • Participation in balance training or neurological/physiotherapy programs within the last 6 months
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
2 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • patients with hypermobility

    Other: no intervention

  • Control group

    Other: no intervention

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Performance in the One-Leg Stance Test

    Assesses static balance capacity and the impact of a simultaneous cognitive task on postural control.

    Time frame: 0 day

  2. Performance in the 30-Second Sit-to-Stand Test

    Evaluates lower extremity muscle endurance and functional strength under cognitive load

    Time frame: 0 day

  3. Performance in the Timed Up and Go (TUG) test

    Measures dynamic balance, mobility, and the ability to maintain performance during divided attention.

    Time frame: 0 day

  4. Dual Task Cost (DTC) percentage

    Quantifies the percentage change in performance when a cognitive task is added, reflecting dual-task interference.

    Time frame: 0 day

Secondary outcomes

  1. Berg Balance Scale (BBS):

    Provides a comprehensive evaluation of functional balance through various static and dynamic tasks. The maximum score is 56. Higher scores indicate that good balance.

    Time frame: 0 day

  2. Activities-specific Balance Confidence Scale (ABC-16)

    Reflects the individual's perceived confidence in performing daily activities without losing balance.The maximum score is 100, the minimum score is 0. Higher scores indicate that high confidence patient's balance.

    Time frame: 0 day

  3. Falls Efficacy Scale-International (FES-I):

    Assesses fear of falling during daily life activities, indicating fall-related psychological concerns. Higher scores indicate that high degree fear of falling

    Time frame: 0 day

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Aug 2025, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2025
First posted
Jul 1, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
Aug 1, 2025
CompletionEst.
Aug 1, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07044999
Lead sponsor
Beylikduzu State Hospital
Responsible party
Busra Sirin (Principle Investigator, Beylikduzu State Hospital) — Principal investigator
First posted
Jul 1, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
Aug 1, 2025 (estimated)
Completion
Aug 1, 2025 (estimated)
Last update
Jul 1, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion